Press Release

Avidity Biosciences Closes $100 Million Series C

November 13, 2019

Palo Alto – November 13, 2019 – Cooley advised Avidity Biosciences on its $100 million Series C financing round. Josh Seidenfeld led the Cooley team advising the company along with Matt Fleming, Jeremy Gentile and Darwin Ng.

Avidity is pioneering antibody-oligonucleotide conjugates (AOC) for the treatment of rare muscle disorders and other serious diseases. The company’s lead research program addresses myotonic dystrophy type I, a disease with no approved treatment options. 

“Using our AOC platform, we can unlock new potential for RNA therapeutics by efficiently targeting muscle and immune cells,” said Avidity president and CEO Sarah Boyce in a news release. “These funds will enable Avidity to advance our growing proprietary portfolio of multiple programs.”

RTW Investments led the financing round. New investors including Cormorant Asset Management, CureDuchenne, Logos Capital, Perceptive Advisors and ST Pharm also participated in the financing, as did existing investors Alethea Capital, Alexandria Venture Investments, Boxer Capital of Tavistock Group, Brace Pharma Capital, EcoR1, Partner Fund Management, Capital and Takeda Ventures. 

Eli Lilly and Company also contributed $15 million in connection with a research collaboration agreement signed with Avidity earlier this year, under which the companies are partnering to use Avidity’s technology to pursue therapeutic targets initially focused on immunology and other indications.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,000+ lawyers across 15 offices in the United States, Asia and Europe.


This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.